Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fujifilm Diosynth Expands R&D Capabilities at its Billingham, UK Site

Published: Friday, April 06, 2012
Last Updated: Friday, April 06, 2012
Bookmark and Share
Company has completed the first phase of a $4.5m investment in new equipment and laboratories.

Fujifilm Diosynth Biotechnologies has completed the first phase of a $4.5m investment in new equipment and laboratories at its Billingham, UK site.

This expansion reinforces the commitment to lead the global Biologics CMO industry through continuous innovation and implementation of new technologies, service delivery and quality, as announced by Japan-based parent company, FUJIFILM Corporation.

The investment includes a complete refurbishment of its microbial fermentation laboratory, which has been totally refitted, including 8 new in-situ sterilisable 20L Sartorius Stedim Biotech fermenters, and a number of fully-instrumented DASGIP parallel bench-top high-throughput units.

In addition, a new suite of research and development laboratories has been installed for process development work, with a corresponding increase in the company's R&D workforce by 50 to over 150 in the last 12 months to support its growing business.

The company expects to further add to this over the coming year at both its Billingham and North Carolina sites.

Mark Carver, PhD, Senior Vice President Research, Development & Innovation said "this investment is in response to our growing innovation activity and to increasing demand from customers for our expertise fast-track development of cost-effective processes for the manufacture of biologics. We are committed to continue to develop leading technology which will deliver benefits to our customers and their patients".


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fujifilm Diosynth Announces Collaboration on a New 20,000-Liter Microbial Biologics Facility
Company has announced collaboration with MSD to invest in and operate a large-scale microbial-biologics facility for supply of active pharmaceutical ingredient (API) to its customers.
Tuesday, June 07, 2016
FUJIFILM Completes Acquisition of Kalon Biotherapeutics
Acquisition enhances Texas’ growing reputation as a global biotechnology leader.
Friday, December 19, 2014
Fujifilm Diosynth Biotechnologies Continues Expansion of R&D Facilities
Company invests more than US$5.6M in new laboratories and equipment.
Wednesday, June 25, 2014
Fujifilm Diosynth Biotechnologies’ UK Site Receives Renewed Manufacturing Licence
Licence authorizes commercial manufacturing at the company’s Billingham, UK site.
Thursday, October 10, 2013
Fujifilm Diosynth Biotechnologies Manufactures a New Licensed Biopharmaceutical
ThromboGenics' has received FDA approval for the launch of JETREA® in the USA.
Thursday, November 15, 2012
Fujifilm Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare
Strategic alliance for the production of antibody drug conjugates.
Thursday, October 25, 2012
Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!